Follow
Yazead Buhidma
Yazead Buhidma
Verified email at kcl.ac.uk
Title
Cited by
Cited by
Year
Pain in Parkinson's disease: new concepts in pathogenesis and treatment
K Rukavina, V Leta, C Sportelli, Y Buhidma, S Duty, M Malcangio, ...
Current opinion in neurology 32 (4), 579-588, 2019
892019
Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease
Y Buhidma, K Rukavina, KR Chaudhuri, S Duty
NPJ Parkinson's disease 6 (1), 1, 2020
582020
Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
J Lama, Y Buhidma, EJR Fletcher, S Duty
Neuronal Signaling 5 (4), NS20210026, 2021
372021
Why are antidepressant drugs effective smoking cessation aids?
M Shoaib, Y Buhidma
Current Neuropharmacology 16 (4), 426-437, 2018
172018
Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia
E Clarke, C Jantrachotechatchawan, Y Buhidma, M Broadstock, L Yu, ...
Neurochemistry international 129, 104502, 2019
122019
Varenicline, the clinically effective smoking cessation agent, restores probabilistic response reversal performance during withdrawal from nicotine
A Jackson, S Silk, Y Buhidma, M Shoaib
Addiction Biology 22 (5), 1316-1328, 2017
112017
Periaqueductal grey and spinal cord pathology contribute to pain in Parkinson’s disease
Y Buhidma, C Hobbs, M Malcangio, S Duty
npj Parkinson's Disease 9 (1), 69, 2023
52023
How can we improve on modeling nicotine addiction to develop better smoking cessation treatments?
M Shoaib, Y Buhidma
International Review of Neurobiology 126, 121-156, 2016
22016
Insight gained from using animal models to study pain in Parkinson's disease.
Y Buhidma, J Lama, S Duty
International Review of Neurobiology 174, 99-118, 2024
2024
Investigating pain in Parkinson's disease and unravelling the underlying mechanisms
YB Buhidma
King's College London, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–10